Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alkermes Plc (ALKS)

Alkermes Plc (ALKS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Alkermes Plc 1 BURLINGTON ROAD CONNAUGHT HOUSE DUBLIN L2 DUBLIN 4 IRL

P: 353-1772-8000

Description:

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag, a wholly owned division of Johnson & Johnson; and VIVITROL the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes.

Key Statistics

Overview:

Market Capitalization, $K 3,196,765
Shares Outstanding, K 157,787
Annual Sales, $ 1,171 M
Annual Net Income, $ -196,620 K
Last Quarter Sales, $ 412,730 K
Last Quarter Net Income, $ -5,350 K
60-Month Beta 1.97
% of Insider Shareholders 4.71%
% of Institutional Shareholders 94.64%
Float, K 150,355
% Float 95.29%

Growth:

1-Year Return -41.68%
3-Year Return -66.77%
5-Year Return -70.29%
5-Year Revenue Growth 89.23%
5-Year Earnings Growth 275.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.83 on 02/13/20
Next Earnings Date N/A
Earnings Per Share ttm 0.08
EPS Growth vs. Prev Qtr 413.64%
EPS Growth vs. Prev Year 305.88%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 2-1 on 05/15/00

ALKS Ratios

Ratio
Price/Earnings ttm 249.13
Price/Earnings forward -65.37
Price/Earnings to Growth N/A
Return-on-Equity % 1.58%
Return-on-Assets % 0.97%
Profit Margin % -16.79
Net Margin % -22.00
Debt/Equity 0.26
Price/Sales 2.69
Price/Cash Flow 34.27
Price/Book 2.89
Book Value/Share 6.89
Interest Coverage -13.49
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar